These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38994659)

  • 1. Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis.
    Akdogan N; Balan K; Armagan BY; Gulseren D; Dogan S
    Expert Rev Clin Pharmacol; 2024 Aug; 17(8):755-762. PubMed ID: 38994659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting.
    Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies.
    Lebwohl M; Iversen L; Eidsmo L; Krueger JG; Suárez-Fariñas M; Tomalin L; Kolbinger F; You R; Milutinovic M
    Clin Exp Dermatol; 2024 Jul; 49(8):793-800. PubMed ID: 37820029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.
    Al-Homood IA; Alajlan M; Alberdisi M; Alturki M; Ahmed AA; Zakaria N
    Adv Rheumatol; 2024 Apr; 64(1):34. PubMed ID: 38685124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal.
    Mendes-Bastos P; Morais P; Ferreira P; Loureiro M; Sanganha J; Santiago L; Basto AS; Henrique M
    Dermatol Ther; 2022 Jul; 35(7):e15510. PubMed ID: 35419886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).
    Tveit KS; Duvetorp A; Østergaard M; Skov L; Danielsen K; Iversen L; Seifert O
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):340-354. PubMed ID: 30242921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
    Nguyen T; Churchill M; Levin R; Valenzuela G; Merola JF; Ogdie A; Orbai AM; Scher JU; Kavanaugh A; Kianifard F; Rollins C; Calheiros R; Chambenoit O
    J Rheumatol; 2022 Aug; 49(8):894-902. PubMed ID: 35428722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience.
    Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS
    Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients.
    Huang H; Cai ML; Hong XJ; Zheng LJ; Hu ZL; Yuan T; Li WR; Sheng YJ; Zhang XJ
    Eur J Dermatol; 2020 Oct; 30(5):554-560. PubMed ID: 33021475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland.
    Koskivirta I; Ruotsalainen J; Kurki S; Lakkakorpi P; Salminen-Mankonen H; Pirilä L; Harvima R; Palomäki A
    Scand J Rheumatol; 2023 Sep; 52(5):549-555. PubMed ID: 36644971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
    Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
    Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.